Education
About Us
Working with TipRanks
Follow Us
Elevation Oncology (ELEV)
NASDAQ:ELEV
ELEV Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.24 - $5.83
Previous CloseN/A
Volume1.30M
Average Volume (3M)1.66M
Market Cap
$17.77M
Enterprise Value-$36.59M
Total Cash (Recent Filing)$49.46M
Total Debt (Recent Filing)$31.13M
Price to Earnings (P/E)―
Beta1.75
Next Earnings
May 01, 2025EPS Estimate
-0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.80
Shares Outstanding59,215,794
10 Day Avg. Volume2,721,827
30 Day Avg. Volume1,663,316
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.40
P/FCF Ratio0.00
Enterprise Value/Market Cap-2.06
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.91
Forecast
1Y Price Target
$1.06Price Target Upside253.33% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
---
Bulls Say, Bears Say
Bulls Say
Financial StabilityThe company's cash runway has been extended into the second half of 2026 due to strategic decisions, ensuring financial stability.
Market OpportunityThe HER3 target is considered de-risked, given the success of similar drugs in treating other types of cancer, presenting large market opportunities.
Strategic ShiftManagement's prompt reaction to end the EO-3021 program at an early point is viewed positively.
Bears Say
Clinical DevelopmentElevation Oncology, Inc. announced the discontinuation of clinical development for their lead asset, EO-3021, due to insufficient competitive benefit-risk profile based on updated trial data.
Stock ValuationThe price target for Elevation Oncology, Inc. has been lowered from $9 to $1 following the removal of all value attributed to EO-3021.
Workforce ReductionThe company is reducing its workforce by approximately 70% and is considering strategic options to maximize shareholder value.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
ELEV FAQ
What was Elevation Oncology’s price range in the past 12 months?
Elevation Oncology lowest stock price was $0.24 and its highest was $5.83 in the past 12 months.
What is Elevation Oncology’s market cap?
Elevation Oncology’s market cap is $17.77M.
When is Elevation Oncology’s upcoming earnings report date?
Elevation Oncology’s upcoming earnings report date is May 01, 2025 which is in 37 days.
How were Elevation Oncology’s earnings last quarter?
Elevation Oncology released its earnings results on Mar 06, 2025. The company reported -$0.18 earnings per share for the quarter, beating the consensus estimate of -$0.223 by $0.043.
Is Elevation Oncology overvalued?
According to Wall Street analysts Elevation Oncology’s price is currently Undervalued.
Does Elevation Oncology pay dividends?
Elevation Oncology does not currently pay dividends.
What is Elevation Oncology’s EPS estimate?
Elevation Oncology’s EPS estimate is -0.19.
How many shares outstanding does Elevation Oncology have?
Elevation Oncology has 59,215,794 shares outstanding.
What happened to Elevation Oncology’s price movement after its last earnings report?
Elevation Oncology reported an EPS of -$0.18 in its last earnings report, beating expectations of -$0.223. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Elevation Oncology?
Currently, no hedge funds are holding shares in ELEV
---
Elevation Oncology Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$1.06 (253.33% Upside)
$1.06 (253.33% Upside)
Blogger Sentiment
Bullish
ELEV Sentiment 100%
Sector Average 69%
Sector Average 69%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 7.7%
Last 30 Days ▼ 7.7%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-93.55%
12-Months-Change
Fundamentals
Return on Equity
-77.48%
Trailing 12-Months
Asset Growth
7.34%
Trailing 12-Months
Company Description
Elevation Oncology
Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion. Elevation Oncology, Inc. was incorporated in 2019 and is based in New York, New York.
---
ELEV Stock 12 Month Forecast
Average Price Target
$1.06
▲(253.33% Upside)
Technical Analysis
Best Analysts Covering ELEV
1 Year
1 Year Success Rate
2/8 ratings generated profit
1 Year Average Return
-44.55%
reiterated a buy rating 19 days ago
Copying Marc Frahm's trades and holding each position for 1 Year would result in 25.00% of your transactions generating a profit, with an average return of -44.55% per trade.
---